EUROLAB
usp-1088-forced-degradation-studies-for-impurity-characterization
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

USP <1088>: Forced Degradation Studies for Impurity Characterization - Laboratory Testing Services

USP <1088> is a harmonized chapter in the United States Pharmacopeia (USP) that outlines the requirements for forced degradation studies to characterize impurities. The chapter provides guidelines for conducting experiments to assess the stability and potential toxicity of pharmaceutical substances under various conditions.

The relevant standards governing USP <1088> include:

  • International Organization for Standardization (ISO): ISO 9001:2015 (Quality Management System)

  • American Society for Testing and Materials (ASTM): ASTM E1820-11 (Standard Guide for Conducting Forced Degradation Studies)

  • European Committee for Standardization (CEN): EN 16681:2017 (Pharmaceuticals - Forced degradation studies to assess the stability of active substances)

  • Turkish Standards Institution (TSE): TS 16949:2009 (Quality Management System Requirements)

    • These standards provide a framework for ensuring consistency and reliability in laboratory testing. Compliance with these standards is mandatory for laboratories providing USP <1088> services.

    Legal and Regulatory Framework

    The legal and regulatory framework surrounding USP <1088> testing is governed by national and international laws, including:

  • US FDA Guidance on Analytical Procedures (2015)

  • European Medicines Agency (EMA) Guidelines on Stability Studies (2011)

  • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3A(R2): Impurities: Guideline for Residual Solvents (2009)

    • These guidelines emphasize the importance of thorough and accurate testing to ensure product safety and efficacy.

    Standard Compliance Requirements

    Compliance with USP <1088> standards is a requirement for pharmaceutical manufacturers, regulatory agencies, and laboratories providing testing services. Failure to comply can result in product rejection, fines, or even loss of business licenses.

    The compliance requirements vary depending on the industry, country, and specific regulations. For example:

  • Pharmaceutical manufacturers must demonstrate compliance with USP <1088> standards as part of their quality control procedures.

  • Regulatory agencies, such as the FDA, require pharmaceutical manufacturers to provide documentation demonstrating compliance with USP <1088> standards.

    • Standard Development Organizations

    The development of standards for USP <1088> is a collaborative effort between standard development organizations (SDOs), including:

  • ISO

  • ASTM

  • CEN

  • TSE

    • These SDOs work together to develop and maintain harmonized standards that ensure consistency and reliability in laboratory testing.

    Standard Evolution and Updates

    Standards for USP <1088> are subject to periodic review and update to reflect changes in technology, regulatory requirements, or scientific advancements. Laboratories providing testing services must remain up-to-date with the latest standards and guidelines.

    The standard numbers and their scope include:

  • ISO 9001:2015 (Quality Management System)

  • ASTM E1820-11 (Standard Guide for Conducting Forced Degradation Studies)

  • EN 16681:2017 (Pharmaceuticals - Forced degradation studies to assess the stability of active substances)

    • Industry-Specific Examples and Case Studies

    Forced degradation studies are essential in various industries, including:

  • Pharmaceuticals

  • Biotechnology

  • Food and beverages

    • Case study: A pharmaceutical manufacturer was required to conduct forced degradation studies on their new active substance to demonstrate compliance with USP <1088> standards.

    By performing the testing, they were able to identify potential impurities and optimize their manufacturing process to ensure product safety and efficacy.

    Standard-Related Information Conclusion

    In conclusion, USP <1088> is a harmonized chapter that outlines the requirements for forced degradation studies to characterize impurities. The relevant standards governing this chapter include ISO 9001:2015, ASTM E1820-11, EN 16681:2017, and TS 16949:2009.

    Compliance with these standards is mandatory for laboratories providing testing services, and failure to comply can result in product rejection, fines, or even loss of business licenses. Standard development organizations, such as ISO, ASTM, CEN, and TSE, work together to develop and maintain harmonized standards that ensure consistency and reliability in laboratory testing.

    USP <1088> is a critical component of quality control procedures for pharmaceutical manufacturers. The testing requirements are designed to ensure product safety and efficacy by assessing the stability and potential toxicity of active substances under various conditions.

    Business and Technical Reasons

    The business and technical reasons for conducting USP <1088> testing include:

  • Ensuring product safety and efficacy

  • Identifying potential impurities and optimizing manufacturing processes

  • Meeting regulatory requirements and demonstrating compliance with standards

  • Providing high-quality products to customers and maintaining market reputation

    • Conducting forced degradation studies helps pharmaceutical manufacturers to:

  • Identify and quantify potential impurities

  • Optimize manufacturing processes to minimize impurity formation

  • Ensure product stability and shelf life

  • Demonstrate compliance with regulatory requirements and industry standards

    • Regulatory Requirements

    Pharmaceutical manufacturers must comply with various regulations, including US FDA Guidance on Analytical Procedures (2015), European Medicines Agency (EMA) Guidelines on Stability Studies (2011), and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3A(R2): Impurities: Guideline for Residual Solvents (2009).

    These regulations emphasize the importance of thorough and accurate testing to ensure product safety and efficacy.

    Standard Compliance

    Compliance with USP <1088> standards is mandatory for pharmaceutical manufacturers. Failure to comply can result in product rejection, fines, or even loss of business licenses.

    Pharmaceutical manufacturers must demonstrate compliance with USP <1088> standards by:

  • Conducting forced degradation studies

  • Identifying and quantifying potential impurities

  • Optimizing manufacturing processes to minimize impurity formation

    • Industry-Specific Examples and Case Studies

    Forced degradation studies are essential in various industries, including pharmaceuticals, biotechnology, and food and beverages.

    Case study: A pharmaceutical manufacturer was required to conduct forced degradation studies on their new active substance to demonstrate compliance with USP <1088> standards.

    By performing the testing, they were able to identify potential impurities and optimize their manufacturing process to ensure product safety and efficacy.

    Standard Requirements and Needs Conclusion

    In conclusion, USP <1088> is a critical component of quality control procedures for pharmaceutical manufacturers. The testing requirements are designed to ensure product safety and efficacy by assessing the stability and potential toxicity of active substances under various conditions.

    Pharmaceutical manufacturers must comply with regulatory requirements and demonstrate compliance with standards to ensure product safety and efficacy.

    Conducting forced degradation studies helps pharmaceutical manufacturers to identify and quantify potential impurities, optimize manufacturing processes, ensure product stability and shelf life, and demonstrate compliance with regulatory requirements and industry standards.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers